Daré Bioscience, Inc. Announces Asset Transfer Agreement with Hydra Biosciences, Inc. for CatSper Contraceptive Target
CatSper antagonist has potential to provide pregnancy prevention via administration to either women or men as a novel, rapidly reversible, non-hormonal contraceptive
“CatSper represents a novel target for non-hormonal contraceptives for both men and women,” said Dr.
“Hydra Biosciences is excited to be providing these assets to Daré, whose focus on women’s reproductive and sexual health makes it a natural fit for this novel approach to non-hormonal contraception,” said
“Our human clinical development activities remain focused on our lead programs Ovaprene® and Topical 5% Sildenafil Citrate Cream. In parallel, we continue to screen, identify, and access technology that is highly differentiated and novel,” said
About Hydra Biosciences
Hydra Biosciences is a biopharmaceutical company based in
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive and sexual health. The company’s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes two potential first-in-class candidates currently in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring, and Topical 5% Sildenafil Citrate Cream, a potential treatment for female sexual arousal disorder utilizing the same active ingredient as Viagra®. To learn more about Daré’s full portfolio of women’s health products, and mission to deliver novel therapies for women, please visit www.darebioscience.com.
All statements contained in this press release, other than statements of historical fact, are "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including, without limitation, statements relating to Daré's ability to leverage assets acquired from Hydra Biosciences to develop novel, non-hormonal contraceptives, to access non-dilutive funding to advance development of CatSper-based product candidates, and to continue to identify, access and advance development of other novel assets that have the potential to address unmet needs in women’s reproductive and sexual health. Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such statements as a result of various important factors, including the uncertainties inherent in the development of novelpharmacological agents, such as the timing of initiation and completion of clinical trials, whether preliminary research or results of early clinical trials will be indicative of results of later clinical trials, and expectations for regulatory approvals and market demand; availability of non-dilutive funding for CatSper-based contraceptives research; availability of additional capital necessary to advance Daré’s product candidates through development and support expansion of its product candidate portfolio; and other factors discussed in the "Risk Factors" section of Daré's quarterly report on Form 10-Q and annual report on Form 10-K filed with the
Investors on behalf of Daré
Media on behalf of Daré
Source: Daré Bioscience
Source: Dare Bioscience, Inc.